vericiguat (Verquvo)
Jump to navigation
Jump to search
Indications
- adjunctive treatment for left ventricular systolic dysfunction[1]
Contraindications
- of no benifit for treatment of left ventricular diastolic dysfunction[2]
Dosage
Adverse effects
Mechanism of action
- soluble guanylate cyclase stimulator
- enhances intracellular cyclic GMP pathway
More general terms
References
- ↑ Jump up to: 1.0 1.1 Armstrong PW. Pieske N, Anstrom KJ et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020; 382:1883-1893. Mar 28; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32222134 https://www.nejm.org/doi/10.1056/NEJMoa1915928
Butler J, Anstrom KJ Armstrong PW Comparing the benefit of novel therapies across clinical trials: Insights from the VICTORIA trial. Circulation 2020 Mar 28; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/32223438 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047086 - ↑ Jump up to: 2.0 2.1 Armstrong PW et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial. JAMA 2020 Oct 20; 324:1512. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33079152 https://jamanetwork.com/journals/jama/article-abstract/2771900
- ↑ FDA Approvals, Highlights, and Summaries: Family Medicine Medscape - Feb 17, 2022 https://reference.medscape.com/viewarticle/967605